Results 21 to 30 of about 1,408,984 (372)

Naltrexone Implant for Opioid Use Disorder [PDF]

Neurology International, 2021
The continued rise in the availability of illicit opioids and opioid-related deaths in the United States has left physicians, researchers, and lawmakers desperate for solutions to this ongoing epidemic. The research into therapeutic options for the treatment of opioid use disorder (OUD) began with the introduction of methadone in the 1960s.
Amber N. Edinoff, Catherine A. Nix, Claudia V. Orellana, Samantha M. StPierre, Erin A. Crane, Blaine T. Bulloch, Elyse M. Cornett, Rachel L. Kozinn, Adam M. Kaye, Kevin S. Murnane, Alan D. Kaye   +10 more
openaire   +3 more sources

Adverse maternal environment alters Oprl1 variant expression in mouse hippocampus

The Anatomical Record, Volume 306, Issue 1, Page 162-175, January 2023., 2023
Abstract An adverse maternal environment (AME) and Western diet (WD) in early life predispose offspring toward cognitive impairment in humans and mice. Cognitive impairment associates with hippocampal dysfunction. An important regulator of hippocampal function is the hippocampal Nociceptin/Orphanin FQ (N/OFQ) system. Previous studies find links between
Xingrao Ke, Yingliu Huang, Qi Fu, Amber Majnik, Venkatesh Sampath, Robert H. Lane   +5 more
wiley   +1 more source

Medication Treatment of Opioid Use Disorder [PDF]

Biological Psychiatry, 2020
Opioid use disorder (OUD) is a chronic, relapsing condition, often associated with legal, interpersonal, and employment problems. Medications demonstrated to be effective for OUD are methadone (a full opioid agonist), buprenorphine (a partial agonist), and naltrexone (an opioid antagonist).
James Bell, John Strang
openaire   +5 more sources

Structure‐guided identification of a selective sulfonamide‐based inhibitor targeting the human carbonic anhydrase VA isoform

Archiv der Pharmazie, Volume 356, Issue 1, January 2023., 2023
Combining ligand‐based and structure‐based methodologies, the applied virtual screening approach identified a collection of sulfonamides targeting the human carbonic anhydrase (hCA) VA isoform. 2‐(3,4‐Dihydro‐2H‐quinolin‐1‐yl)‐N‐(4‐sulfamoylphenyl)acetamide was identified as a potent and selective lead compound as a candidate for further exploitation ...
Laura De Luca, Andrea Angeli, Federico Ricci, Claudiu T. Supuran, Rosaria Gitto   +4 more
wiley   +1 more source

3‐[3‐(Phenalkylamino)cyclohexyl]phenols: Synthesis, biological activity, and in silico investigation of a naltrexone‐derived novel class of MOR‐antagonists

Archiv der Pharmazie, Volume 356, Issue 1, January 2023., 2023
Based on a simplified version of the morphinan scaffold, 3‐[3‐(phenalkylamino)cyclohexyl]phenol analogues were designed, synthesized and evaluated for their µ‐opioid receptor (MOR) antagonist activity in vitro and in silico. Docking studies indicate a peculiar combination of C‐1 stereochemistry and N‐substitutions as feasibly essential for MOR‐ligand ...
Graziella Tocco, Antonio Laus, Maksims Vanejevs, Anastasija Ture, Rafaela Mostallino, Nicholas Pintori, Maria Antonietta De Luca, M. Paola Castelli, Gaetano Di Chiara   +8 more
wiley   +1 more source

An Effective and Safe Novel Treatment of Opioid Use Disorder: Unilateral Transcranial Photobiomodulation

Frontiers in Psychiatry, 2021
Background: The opioid epidemic is a global tragedy even with current treatments, and a novel, safe, and effective treatment would be welcomed. We report here our findings from our second randomized controlled trial to evaluate unilateral transcranial ...
Fredric Schiffer, Fredric Schiffer, Fredric Schiffer, Alaptagin Khan, Alaptagin Khan, Elizabeth Bolger, Edward Flynn, William P. Seltzer, Martin H. Teicher, Martin H. Teicher   +9 more
doaj   +1 more source

Co-prevalence of Substance Use Disorders and Common AxisⅠDisorders in Yunnan's Drug Users [PDF]

Zhongguo quanke yixue, 2022
Background Mental disorders in drug users have received increasing attention. However, there are no any epidemiologic data available in regard to substance use disorders (SUD) and other mental disorders in drug users in Yunnan, one region that is hit ...
ZHANG Guanbai, ZHENG Ling, YANG Liping, ZHOU Qin, WANG Fei, HE Liangze, CHENG Xuan, CHA Li, LI Xinyue
doaj   +1 more source

Prevalence and determinants of opioid use disorder among long-term opiate users in Golestan Cohort Study

BMC Psychiatry, 2023
Background Number of opiate users worldwide has doubled over the past decade, but not all of them are diagnosed with opioid use disorder. We aimed to identify the prevalence and risk factors for OUD after ten years of follow-up.
Saba Alvand, Masoumeh Amin-Esmaeili, Hossein Poustchi, Gholamreza Roshandel, Yasaman Sadeghi, Vandad Sharifi, Farin Kamangar, Sanford M. Dawsey, Neal D. Freedman, Christian C. Abnet, Afarin Rahimi-Movaghar, Reza Malekzadeh, Arash Etemadi   +12 more
doaj   +1 more source

Development of an integrated cognitive behavioral therapy for anxiety and opioid use disorder: Study protocol and methods [PDF]

, 2017
Opioid use disorder is a highly disabling psychiatric disorder, and is associated with both significant functional disruption and risk for negative health outcomes such as infectious disease and fatal overdose. Even among those who receive evidence-based
Barlow, David H., Fitzmaurice, Garrett M., Greenfield, Shelly F., McHugh, R. Kathryn, Votaw, Victoria R., Weiss, Roger D.   +5 more
core   +1 more source

Neuroimaging for differential diagnosis of transient neurological attacks

Brain and Behavior, Volume 12, Issue 12, December 2022., 2022
Abstract Background Rapid yet comprehensive neuroimaging protocols are required for patients with suspected acute stroke. However, stroke mimics can account for approximately one in five clinically diagnosed acute ischemic strokes and the rate of thrombolyzed mimics can be as high as 17%.
Ying Wang, Hao Zha
wiley   +1 more source